Cyclic amine substituted oxazolidinone CETP inhibitor

US9221834B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Zhijian Lu · Clinton, US
• Yi-Heng Chen · Whippany, US
• Cameron Smith · Lawrenceville, US
• Hong Li · Edison, US
• Christopher F. Thompson · Arlington, US
• Julianne A. Hunt · Scotch Plains, US
• Florida Kallashi · Yonkers, US
• Ramzi F. Sweis · Vernon Hills, US
• Peter J. Sinclair · Highland Park, US
• Samantha E. Adamson · Charlottesville, US
• Guizhen Dong
• Debra L. Ondeyka · Fanwood, US
• Xiaoxia Qian · New York, US
• Wanying Sun · Edison, US
• Petr Vachal · Summit, US
• Kake Zhao · Westfield, US

Key dates

• Filing date: Oct 25, 2011
• Grant date: Dec 29, 2015
• Expiry date: Apr 2, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, A3 is a substituted phenyl group or indanyl group. Formula (I).